Heron Therapeutics is trading 10.27% down at $0.30 amid broad risk-off trading.
- No company-specific announcement for October 22, 2026, was identified; Heron’s investor-relations page lists its August 10 second-quarter results as the latest release.
- Oil prices are rising amid Strait of Hormuz supply concerns, while investors reassess AI-related spending.
- Market coverage describes pressure across U.S. equities, making broad market weakness the likeliest context, not a confirmed company-specific catalyst.